Rezdiffra (Resmetirom) Seasonal Use Considerations

What Is Rezdiffra and Why Does Season Matter for Women?

Rezdiffra (resmetirom) is the first drug the FDA has approved specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis (F2-F3). It works by selectively activating thyroid hormone receptor beta (THR-beta) in the liver, which reduces liver fat, lowers atherogenic lipids, and slows fibrosis without meaningfully stimulating the heart or bone.

Season matters for three concrete reasons. First, your liver's metabolic load changes with the calendar. Holiday eating in November through January, for example, raises caloric and saturated-fat intake in a way that counteracts resmetirom's fat-clearing mechanism. Second, vitamin D, which fluctuates with sun exposure, independently modulates hepatic inflammation in MASH. Third, for women specifically, the seasonal overlap with hormonal milestones, such as starting a new hormonal contraceptive in spring or managing perimenopausal weight gain in winter when activity drops, changes the clinical picture in ways that no existing trial has cleanly addressed.

Why Women Are the Primary MASH Population

MASH is not a gender-neutral disease. Women account for roughly 55-65% of MASH diagnoses in clinic-based cohorts, and the hormonal inflection points of perimenopause and menopause accelerate hepatic fat accumulation in ways that estrogen-replete premenopausal women are partially protected from. Estrogen loss after menopause is directly associated with increased visceral adiposity and hepatic steatosis, making postmenopausal women a biologically distinct population for MASH risk.

Women with PCOS carry an additional burden. PCOS-associated hyperinsulinemia, androgen excess, and insulin resistance are independent drivers of NAFLD/MASH, and prevalence estimates suggest up to 70% of women with PCOS have some degree of hepatic steatosis. Resmetirom has not been specifically studied in PCOS populations, and that evidence gap deserves candid acknowledgment.

The MAESTRO-NASH Trial: What the Data Actually Show

Core Results

The MAESTRO-NASH trial, published in the New England Journal of Medicine in 2024, enrolled 966 adults with biopsy-confirmed MASH and stage F1b to F3 fibrosis. The co-primary endpoints were NASH resolution without worsening fibrosis, and fibrosis improvement by at least one stage without worsening NASH activity.

At 52 weeks:

• NASH resolution: 26.1% on resmetirom 80 mg vs. 9.7% on placebo (p <0.001)
• NASH resolution: 29.9% on resmetirom 100 mg vs. 9.7% on placebo (p <0.001)
• Fibrosis improvement: 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% placebo

Both doses significantly reduced LDL-C, non-HDL-C, and triglycerides as secondary outcomes, a finding with direct relevance to perimenopausal and postmenopausal women whose cardiovascular risk rises sharply after estrogen withdrawal.

Sex-Specific Data: An Evidence Gap

Here is what the trial did not do cleanly: pre-specified subgroup analyses by sex, menopausal status, or hormonal contraceptive use were not published in the primary manuscript. The trial enrolled roughly 60% women, which is appropriate for the disease population, but sex-stratified efficacy and safety data remain unpublished at time of writing. That means every dose and response projection in women is currently extrapolated from the overall trial population, not directly studied by sex.

This gap is clinically meaningful. THR-beta activation alters thyroid hormone signaling in the liver, and thyroid physiology differs by sex and by hormonal status. Women are five to eight times more likely than men to have autoimmune thyroid disease, and the interaction between resmetirom's THR-beta agonism and pre-existing Hashimoto thyroiditis has not been formally studied. Until sex-disaggregated trial data exist, women with thyroid co-morbidity on resmetirom warrant closer monitoring than the current label requires.

Seasonal Considerations: A Month-by-Month Framework

Winter (December through February): Holiday Eating and Vitamin D Nadir

Winter is the highest-risk season for dietary backsliding in MASH. Saturated fat and simple sugar intake rise during the holiday period, which directly competes with resmetirom's mechanism of reducing hepatic de novo lipogenesis. One practical strategy: schedule your next lipid panel and ALT check in January, not just at your annual visit, so dietary drift shows up in the data and can be addressed before it compounds.

Vitamin D levels in northern latitudes typically reach their seasonal nadir in January through March. Vitamin D deficiency is independently associated with worse MASH histology and greater hepatic inflammation. If your 25-OH vitamin D level falls below 30 ng/mL, supplementation to above 40 ng/mL is a reasonable adjunct while on resmetirom, though no randomized trial has tested this combination specifically.

Women in perimenopause and postmenopause have an additional winter consideration: cold-driven activity reduction compounds existing visceral fat accumulation from estrogen withdrawal. Resmetirom reduces liver fat but does not reverse visceral adiposity, so the lifestyle component cannot be delegated to the drug.

Spring (March through May): Contraception Reviews and Thyroid Lab Timing

Spring is when many women start new hormonal contraceptive methods or transition off them as they consider pregnancy. This matters for resmetirom because:

1. Resmetirom is contraindicated in pregnancy and requires reliable contraception for women of reproductive potential.
2. Combined oral contraceptives raise thyroid-binding globulin (TBG), which changes how thyroid labs are interpreted in women already on resmetirom who have thyroid disease.
3. Spring thyroid lab timing captures the transition out of the vitamin D nadir and gives you a baseline before summer's metabolic acceleration.

Spring also brings increased physical activity for many women, which independently improves hepatic fat. The combination of resmetirom plus sustained aerobic exercise has not been studied in a randomized trial, but metabolic logic supports an additive effect on liver fat reduction.

Summer (June through August): Heat, GI Symptoms, and Dehydration

The most common side effects of resmetirom in MAESTRO-NASH were nausea (26.2% at 100 mg) and diarrhea (28.3% at 100 mg) versus 12.7% and 16.0% for placebo, respectively. Both are significantly worsened by summer heat and dehydration.

Practical summer management points:

• Take resmetirom with food, especially during summer outdoor activities.
• Maintain fluid intake above 2 liters per day in hot weather; GI side effects intensify with even mild dehydration.
• If you are traveling across time zones in summer, resmetirom's once-daily dosing is flexible but should stay within a consistent 2-to-4-hour window.
• Sun exposure improves vitamin D levels, which may modestly benefit MASH; this is not a reason to skip sunscreen, but it is a reason to get outdoor activity when you can.

Women who are postmenopausal should also note that thermoregulation is impaired after menopause, making summer heat management harder independent of any medication. This is a population where resmetirom's GI side effects may compound with vasomotor symptoms to reduce tolerability, and a proactive conversation with your prescriber before summer is sensible.

Fall (September through November): Metabolic Resets and Annual Liver Imaging

Fall is the most metabolically active season for resetting habits after summer disruptions, and it is the natural time to schedule annual liver-related assessments. For women on resmetirom, a fall assessment should include:

• Fasting lipid panel (resmetirom reduces LDL-C by approximately 13-16% and triglycerides by 19-22% in MAESTRO-NASH)
• ALT and AST
• Thyroid-stimulating hormone (TSH) with free T4
• 25-OH vitamin D ahead of winter
• Discussion of any changes in menopausal status or hormonal therapies

If your prescriber uses FibroScan or MRI-PDFF to track liver fat non-invasively, fall is a reasonable time for imaging given that the summer's improved activity and vitamin D levels will be captured, and you have a full year of drug data.

Resmetirom and Female-Specific Conditions

PCOS

Women with PCOS are an under-studied but high-priority population for resmetirom. Insulin resistance, the central driver of MASH in PCOS, is also the mechanism resmetirom addresses indirectly through hepatic fat clearance. Metformin, widely used in PCOS for insulin sensitization, has independently shown modest hepatic benefit in NAFLD but has not been tested in combination with resmetirom. The two drugs do not have a known pharmacokinetic interaction, but combined data are absent.

For women with PCOS who are of reproductive age, the contraception requirement is especially pressing. Resmetirom must not be used during pregnancy, and women with PCOS who use hormonal contraception (especially progestin-only methods) should know that some progestins worsen insulin resistance, which counteracts MASH treatment. An ACOG-aligned combined hormonal method is generally preferred for PCOS unless there is a contraindication.

Perimenopause and Menopause

The perimenopausal transition begins, on average, in the early-to-mid 40s and lasts four to ten years. During this window, estrogen fluctuation drives accelerated hepatic fat deposition that may unmask or worsen previously subclinical MASH. Women who are diagnosed with MASH for the first time in their late 40s or early 50s should recognize that perimenopausal hormonal shifts are likely contributors, not coincidences.

Resmetirom has not been studied in clinical trials stratified by menopausal status. Whether menopausal hormone therapy (MHT) modifies resmetirom's efficacy is unknown. Oral estrogen raises TBG and can alter the thyroid lab profile, which is relevant for interpreting TSH in women on both MHT and resmetirom. Transdermal estrogen does not raise TBG to the same degree and may be preferred in women with thyroid disease on resmetirom, though this recommendation is extrapolated from general thyroid physiology rather than resmetirom-specific data.

The Menopause Society's 2023 position statement supports MHT for perimenopausal symptoms in appropriate candidates. If you have MASH and are considering MHT, a conversation between your hepatologist and menopause specialist is worth arranging, because estrogen's metabolic and cardiovascular benefits may genuinely intersect with your MASH treatment goals.

Thyroid Disease

Resmetirom selectively agonizes THR-beta, the receptor isoform concentrated in the liver. It does not meaningfully agonize THR-alpha, which governs cardiac and bone metabolism. Despite this selectivity, women with pre-existing autoimmune thyroid disease, Hashimoto thyroiditis, or hypothyroidism on levothyroxine deserve specific monitoring.

Resmetirom may modestly reduce TSH and free T4 by increasing peripheral thyroid hormone action within the liver, which can complicate interpretation of labs in women already on thyroid replacement. The FDA prescribing information does not require specific levothyroxine dose adjustment, but clinical experience suggests checking TSH four to six weeks after starting resmetirom if you are on thyroid replacement therapy, and again at each seasonal transition when your vitamin D level and metabolic rate shift.

Women are five to eight times more likely than men to have autoimmune thyroid disease, making this a women-first monitoring priority rather than an afterthought.

Pregnancy, Lactation, and Contraception

Resmetirom is contraindicated in pregnancy. This is a hard stop, not a soft caution.

Animal reproductive studies showed fetal harm at doses approximating human exposure levels. No adequate human pregnancy data exist. If you become pregnant while taking resmetirom, discontinue immediately and contact your obstetric provider.

Contraception Requirement

The FDA label requires women of reproductive potential to use effective contraception during treatment and for a defined washout period after stopping. "Effective" in this context means methods with a failure rate below 1% per year with typical use, which includes:

• Combined hormonal methods (pill, patch, ring)
• Progestin-only methods (implant, hormonal IUD)
• Copper IUD
• Sterilization

Barrier methods alone (condoms, diaphragm) are not considered adequate given the drug's reproductive risk profile.

Women with PCOS who have irregular cycles should not interpret amenorrhea as evidence of infertility. Ovulation can occur unpredictably, and resmetirom must be covered by reliable contraception regardless of menstrual regularity.

Lactation

Transfer of resmetirom into human breast milk is unknown. Given the potential for serious adverse effects in a nursing infant from a hepatically active thyroid receptor agonist, breastfeeding is not recommended during treatment. This applies across all life stages, including postpartum women who may have developed MASH during pregnancy-related metabolic stress.

Fertility Considerations

No human data exist on resmetirom's effects on female fertility. Women who are actively trying to conceive should discontinue resmetirom, complete the washout period specified in the label, and coordinate with both their hepatologist and reproductive endocrinologist before attempting pregnancy. MASH itself does not categorically preclude pregnancy, but active hepatic fibrosis requires specialist co-management.

Who This Drug Is Right for, and Who Should Wait

Women Who Are Strong Candidates

• Biopsy-confirmed MASH with stage F2 or F3 fibrosis
• BMI <40 on trial enrollment (the MAESTRO-NASH inclusion criterion)
• Perimenopausal or postmenopausal women with MASH and no active pregnancy intent
• Women with PCOS-driven MASH who are on reliable contraception and have not responded adequately to lifestyle modification and metformin alone

Women Who Should Not Start Resmetirom Now

• Pregnant or actively trying to conceive
• Breastfeeding
• Decompensated cirrhosis (F4 with portal hypertension; resmetirom is approved only for F2-F3)
• Active hepatitis B or C requiring treatment (not studied in MAESTRO-NASH)
• Severe, uncontrolled hypothyroidism (discuss with your provider; resmetirom may complicate thyroid management until levels are stable)

Women in the Gray Zone

Women with stage F1 fibrosis, those with concurrent alcohol use disorder, and those with MASH driven primarily by medication (steroids, tamoxifen) were excluded from or underrepresented in MAESTRO-NASH. Off-label use in these populations is premature.

Monitoring Schedule Across the Year

The following monitoring framework is based on the MAESTRO-NASH safety data and clinical pharmacology of resmetirom, adapted for women's physiological needs.

| Season | Labs | Clinical Check | |--------|------|---------------| | Winter (Jan) | ALT, AST, lipid panel, TSH, 25-OH vitamin D | GI side effect review; holiday dietary assessment | | Spring (Mar-Apr) | TSH, free T4, pregnancy test if any doubt | Contraception review; activity plan | | Summer (Jun-Jul) | ALT, AST | Hydration, GI side effect management | | Fall (Sep-Oct) | Full panel: lipids, ALT, AST, TSH, 25-OH vitamin D | Imaging if due; MHT discussion if perimenopausal |

This is a framework, not a substitute for your prescriber's individualized plan. Women with thyroid disease or active hormonal transitions may need more frequent lab reviews.

Resmetirom Drug Interactions Relevant to Women

Resmetirom is a substrate of CYP2C8 and a weak inhibitor of OATP1B1/1B3. For women, the clinically relevant interactions include:

• Statins: Resveratrol-based interactions are theoretical, but OATP1B1 inhibition can raise statin exposure. If you are on rosuvastatin or atorvastatin for perimenopausal cardiovascular risk, your prescriber should review the dose when starting resmetirom.
• Oral contraceptives: No formal interaction studies are published, but combined hormonal contraceptives use hepatic CYP pathways. Monitoring for unexpected contraceptive failure or breakthrough bleeding is appropriate in the first three months.
• Levothyroxine: As above, check TSH four to six weeks after starting resmetirom if you are on thyroid replacement.

The FDA prescribing information contains the complete drug interaction table. Review it with your pharmacist, not just your prescriber, especially if you are on four or more medications.